Liver Cancer Therapeutics Sector: Growth Drivers and Challenges
Growth Drivers
- Growing prevalence of liver cancer
- Rise in incidence of hepatitis B infection in developing countries
- Increasing R&D activities and advancement in cancer therapeutics
Challenges
- High cost and side effects related to certain liver cancer therapies
- Limitations in treatment options with several therapies in clinical trial stage
Liver Cancer Therapeutics Market: Key Insights
|
Base Year |
2024 |
|
Forecast Year |
2025-2037 |
|
CAGR |
18.4% |
|
Base Year Market Size (2024) |
USD 3.54 billion |
|
Forecast Year Market Size (2037) |
USD 31.81 billion |
|
Regional Scope |
|
Browse key industry insights with market data tables & charts from the report:
Frequently Asked Questions (FAQ)
In the year 2025, the industry size of liver cancer therapeutics is estimated at USD 4.09 billion.
Liver Cancer Therapeutics Market size was valued at USD 3.54 billion in 2024 and is likely to cross USD 31.81 billion by 2037, registering more than 18.4% CAGR during the forecast period i.e., between 2025-2037.
North America industry is likely to hold largest revenue share by 2037, owing to high awareness about liver cancer, presence of well-established healthcare infrastructure, and easy drug availability.
The major players in the market are Bristol-Myers Squibb Company, Eisai Co., Ltd., Exelixis, Inc., Merck Sharp & Dohme Corp. (Merck & Co., Inc.), Bayer AG, Zymeworks Inc., F. Hoffmann-La Roche Ltd., Celsion Corporation, Eli Lilly and Company, AstraZeneca, and others.
